Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
06 Mai 2022 - 11:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2022
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
K ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
Financial and Operating Results
On
May 5, 2022, Celyad Oncology SA (the Company) issued a press release announcing its financial and operating results for the first quarter of 2022. A copy of the Companys press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference. The Companys interim consolidated statement of comprehensive income and interim consolidated statement of financial position for the first quarter of 2022 are attached hereto as Exhibit 99.2 and are
incorporated herein by reference.
The information contained in this Current Report on Form
6-K, including Exhibits 99.1 and 99.2, except for the quote of Filippo Petti contained in Exhibit 99.1, is hereby incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA |
|
|
|
|
Date: May 6, 2022 |
|
|
|
By: |
|
/s/ Filippo Petti |
|
|
|
|
|
|
Filippo Petti |
|
|
|
|
|
|
Chief Executive Officer and Financial Officer |
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Celyad (CE) (USOTC:CLYYF)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Celyad SA (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Celyad Oncology Sa